ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Monday, November 18, 2024

10:30AM-12:30PM: Abstract Number: 2467

Elderly Systemic Sclerosis. Clinical Presentation and Outcome

Systemic Sclerosis & Related Disorders – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 1942

Electronic Health Literacy and Its Association with Disease Activity in RMD Patients – a Cross Sectional Study

Health Services Research – ACR/ARP Poster III

10:30AM-12:30PM: Abstract Number: 2013

Elevated Serum Allantoin and Allantoin/uric Acid Ratio as Indicators of Oxidative Stress in Severe Gout and Cardiovascular Comorbidities

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster III

10:30AM-12:30PM: Abstract Number: 1813

Elucidating the Molecular Correlates of Treatment Response in Lupus Nephritis via Imaging Mass Cytometry Proteomics and Machine Learning

SLE – Etiology & Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 1890

Emergency Department Visits for Ambulatory Care Sensitive Conditions by Persons with Rheumatoid Arthritis: A Population-Based Study

Epidemiology & Public Health Poster III

10:30AM-12:30PM: Abstract Number: 1767

Endothelial Cell-Driven JAG/NOTCH Signaling in Localized Scleroderma Patients

Pediatric Rheumatology – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 1944

Enhancing Rheumatology Consultations with AI-Powered Triage: The ReumAI Pilot Study

Health Services Research – ACR/ARP Poster III

10:30AM-12:30PM: Abstract Number: 2106

EP-104IAR (Long-Acting Intra-Articular Injection of Fluticasone Propionate) Shows Sustained Improvement in Pain for Subjects with Moderate Baseline Pain and BMI Less Than 30 in SPRINGBOARD, a Phase 2, Randomized, 24-Week Study of Osteoarthritis of the Knee

Osteoarthritis – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 2123

Epidemiology of Bone Health and Fracture in Gout Patients

Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

10:30AM-12:30PM: Abstract Number: 2434

ESK-001, an Allosteric TYK2 Inhibitor, Maximally Suppresses Type 1 Interferon, a Therapeutic Pathway Central to SLE and CLE

SLE – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 1927

Ethnic and Racial Minorities in Clinical Trials for Autoimmune Connective Tissue Disease Therapeutic Agents

Healthcare Disparities in Rheumatology Poster III

10:30AM-12:30PM: Abstract Number: 1938

Evaluating Diagnostic Performance of Mycobacterium Tuberculosis Derived Cell-free DNA (CF-DNA) for Diagnosis of Osteoarticular Tuberculosis (OATB): A Novel Method

Health Services Research – ACR/ARP Poster III

10:30AM-12:30PM: Abstract Number: 2178

Evaluating the Non-Inferiority of Mycophenolate Mofetil Compared to Methotrexate in Treating Juvenile Localized Scleroderma

Pediatric Rheumatology – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 2179

Evaluation of Diagnostic Concordance Between Telehealth Encounters and In-Person Follow-up Assessments in Pediatric Rheumatology

Pediatric Rheumatology – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 2043

Evaluation of Medication Adherence of FMF Patients Transitioned from a Pediatric Clinic to an Adult Clinic: A Cross-sectional Study

Miscellaneous Rheumatic & Inflammatory Diseases Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].